From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
Vetenskapsnyheter
The Trump administration is moving to restart the specialized LGBTQ+ option for youth who contact the 988 crisis line, but the group that helped pioneer the idea is being shut…
Cassidy targets 340B, Eli Lilly's mysterious retatrutide patient, and more biotech news from The Readout
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans.…
The European Commission is investigating Sanofi for allegedly breaching antitrust rules by running a “misleading” campaign about a flu vaccine.
Dems want to unmask Eli Lilly's obesity drug user, a new genome-editing tool raises ethics questions, and more health news
“They don't make many like Joe Fraumeni anymore,” writes Lawrence Ingrassia, author of “A Fatal Inheritance.”
Medetomidine-laced opioids cause severe, life-threatening withdrawal in jails. Here's why many facilities remain ill-equipped to treat a growing crisis.
A report about unusual access to an experimental obesity drug has raised interest in the condition pulmonary hypertension.
Opinion: ‘The Hot Zone’ led me to work with Ebola patients. Now I have mixed feelings about the book
“The reality of Ebola is simultaneously less sensational and far more challenging than most people imagine,” writes Krutika Kuppalli.
A new charter for the panel that advises the CDC on vaccine use substantially refocuses the responsibilities of the committee, downplaying its role in recommending the use of new vaccines.
Biotech executives reveal concerns over Chinese biotech, the profitability of AI, and the durability of Trump's drug price moves.
Who got exclusive access to Eli Lilly's highly anticipated obesity candidate? And why are drugmakers spending so much on acquisitions? Find out on this week's "Readout LOUD."
Placing new limits on the 340B drug discount program would be a fresh challenge for hospitals as they confront funding cuts.
The Supreme Court sided with the maker of Roundup weedkiller in a ruling expected to block thousands of lawsuits alleging it failed to warn people the product could cause cancer.
Under President Trump, political leaders are exerting more control across federal health agencies.
The unusual access to an experimental drug has captured the attention of the American public as well.
The use of genome editing in early embryos has pulled back the curtain on the role of one of the key genes that orchestrates the first stages of human development,…
A boom in GLP-1s and health care costs, AI-designed hair growth drugs, and more biotech news from The Readout
In this edition of STAT Health Tech: FDA drops enforcement against Whoop, more AI devices get FDA 'breakthrough' label, and more.
The latest pharmaceutical news from the Pharmalot campus via the Pharmalittle newsletter
FDA has granted breakthrough designation to two devices that use generative AI to interpret chest X-rays and draft the radiology reports.
New bill proposes expanding methadone access, $5.7 trillion on U.S. health care, and more health news from Morning Rounds
“Women are fully capable of making difficult decisions, but meaningful choice requires trusted, vetted information,” writes Michelle Sie Whitten of the Global Down Syndrome Foundation.
It's an unusual time to be in the vaccine business. But in the view of those gathered at the BIO conference this week, it’s not altogether a bleak one.